

3rd World Congress on

MIDWIFERY AND WOMEN'S HEALTH

November 13-14, 2017 | London, UK

The molecular classification of women's breast cancer, therapeutic interest, experience of Sidi Bel Abbes, Algeria

Nawel Agher^{1,2}

¹University Djilali Liabés, Sidi Bel Abbes, Algeria

²Ben Hamida Laboratory, Algeria

The heterogeneity of molecular abnormalities presented by breast cancers and the in-depth knowledge of these potential targets is a promising source of targeted therapy. The development of these therapeutic targets makes it possible to envisage the development of customized therapeutic combinations adapted to the intrinsic cancer characteristics. The aim of our work is to carry out a descriptive, histopathological study and to apply the molecular classification. We selected 237 women with breast cancer at the Pathology Department of the Sidi Bel Abbés Hospital Center, Algeria. We could identify for each cancer, the molecular class according to its immunohistochemical profile by the study of hormonal receptors oestrogen and progesterone, the status of the oncogene HER2/neu and completed by the in-situ hybridization by fluorescence (FISH) technique for the cases with HER2 score 2. According to the molecular classification of breast cancers, our sample presents: HER2 positive tumors, whose prognosis was significantly modified by targeted therapies: 35%, Two major types of tumors expressing hormonal (HR) receptors: weakly proliferating and of good prognosis luminal A, and proliferating with a lower luminal B prognosis with: Luminal A- 16% and Luminal B- 29%, Triple-negative tumors (RE-, RP- and HER2-): 20%, completed by studying the markers: CK5/6, P63. The "intrinsic" genomic expression signature that distinguishes several major categories of breast cancers has clearly shown its prognostic and even therapeutic interest in clinical practice. This necessitates the importance of developing the appropriate care for these patients and the installation of the techniques necessary for the choice of therapeutics.

Biography

Nawel Agher has completed his PhD from Djilali Liabés, Sidi Bel Abbes University, Algeria and Postdoctoral studies from Algiers University of Science. She holds the position of Head of Unit of Molecular Biology in the Department of Pathology University Hospital, Sidi bel Abbes and she is a Member of several research laboratories. She has published more than eight papers in reputed journals and over 40 national and international oral communications in several scientific opportunities in the field of Oncology and Molecular Biology. She published her first book under the name "Interest of the Testing of HER-2 in Oncology" in Edition European University. She is Product Specialist (Technical commercial) of Molecular Biology at BH LAB of medical equipment and laboratory reagents.

nag.bhlab@bhinvest.net

Notes: